RxSight, Inc. (RXST) Stock Forecast
Data as of Oct 31, 2026Healthcare · Current price $4.87 (-3.66%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Mar 9, 2026 | Thomas Stephan | Stifel Nicolaus | $9.00 | +85.0% |
| Feb 26, 2026 | David Saxon | Needham | $13.00 | +167.2% |
| Oct 29, 2024 | Adam Seiden | Barclays | $110.00 | +2161.0% |
| Oct 29, 2024 | Curry Baker | Guggenheim | $52.00 | +968.9% |
| Oct 29, 2024 | Anthony Crowdell | Mizuho Securities | $67.00 | +1277.2% |
| Oct 29, 2024 | Young Li | Jefferies | $72.00 | +1380.0% |
| Sep 23, 2024 | Ryan Zimmerman | BTIG | $59.00 | +1112.7% |
| Sep 13, 2024 | David Saxon | Needham | $66.00 | +1256.6% |
| Aug 6, 2024 | Thomas Stephan | Stifel Nicolaus | $65.00 | +1236.1% |
| Aug 6, 2024 | David Saxon | Needham | $54.00 | +1010.0% |
| May 7, 2024 | Steven Lichtman | Oppenheimer | $72.00 | +1380.0% |
| May 7, 2024 | David Saxon | Needham | $75.00 | +1441.6% |
| May 7, 2024 | Tom Stephan | Stifel Nicolaus | $75.00 | +1441.6% |
| May 7, 2024 | Lawrence Biegelsen | Wells Fargo | $68.00 | +1297.7% |
| May 7, 2024 | Ryan Zimmerman | BTIG | $72.00 | +1380.0% |
| May 6, 2024 | Thomas Stephan | Stifel Nicolaus | $68.00 | +1297.7% |
| Dec 13, 2023 | Lawrence Biegelsen | Wells Fargo | $42.00 | +763.3% |
| Jul 12, 2023 | David Saxon | Needham | $34.00 | +598.9% |
Top Analysts Covering RXST
RXST vs Sector & Market
| Metric | RXST | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 3.00 | 2.25 | 2.41 |
| Analyst Count | 8 | 8 | 19 |
| Target Upside | +50.3% | +153002.0% | +21.5% |
| P/E Ratio | -7.58 | 3.48 | 38.49 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $128M | $129M | $130M | 7 |
| 2027-03-31 | $33M | $34M | $35M | 3 |
| 2027-06-30 | $35M | $36M | $37M | 3 |
| 2027-09-30 | $34M | $35M | $36M | 3 |
| 2027-12-31 | $37M | $38M | $39M | 3 |
| 2028-03-31 | $42M | $43M | $44M | 2 |
| 2028-06-30 | $41M | $42M | $43M | 2 |
| 2028-09-30 | $41M | $42M | $43M | 2 |
| 2028-12-31 | $44M | $45M | $46M | 2 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $-1.41 | $-1.32 | $-1.23 | 4 |
| 2027-03-31 | $-0.32 | $-0.31 | $-0.30 | 1 |
| 2027-06-30 | $-0.34 | $-0.33 | $-0.32 | 1 |
| 2027-09-30 | $-0.32 | $-0.31 | $-0.30 | 1 |
| 2027-12-31 | $-0.33 | $-0.32 | $-0.31 | 1 |
| 2028-03-31 | $-0.28 | $-0.27 | $-0.26 | 1 |
| 2028-06-30 | $-0.31 | $-0.30 | $-0.29 | 1 |
| 2028-09-30 | $-0.29 | $-0.28 | $-0.27 | 1 |
| 2028-12-31 | $-0.27 | $-0.26 | $-0.25 | 1 |
Frequently Asked Questions
What is the analyst consensus for RXST?
The consensus among 8 analysts covering RxSight, Inc. (RXST) is Hold with an average price target of $8.00.
What is the highest price target for RXST?
The highest price target for RXST is $110.00, set by Adam Seiden at Barclays on 2024-10-29.
What is the lowest price target for RXST?
The lowest price target for RXST is $9.00, set by Thomas Stephan at Stifel Nicolaus on 2026-03-09.
How many analysts cover RXST?
8 analysts have issued ratings for RxSight, Inc. in the past 12 months.
Is RXST a buy or sell right now?
Based on 8 analyst ratings, RXST has a consensus rating of Hold (3.00/5) with a +50.3% upside to the consensus target of $8.00.
What are the earnings estimates for RXST?
Analysts estimate RXST will report EPS of $-1.32 for the period ending 2026-12-31, with revenue estimated at $129M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.